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Abstract
Background: Treatment with nucleotide analogs is known to be effective in inhibiting HBV replication; however, patients
with chronic hepatitis B (CHB) often show a wide range of clinical responses to these drugs. Therefore, the identification of
an early immunologic marker associated with the clinical outcomes in such cases is critical for the improved clinical
management. In our study, we aimed to investigate whether the viral load in CHB patients affected the ratio of the number
of regulatory T cells (Tregs) to the number of interleukin-17-producing helper (Th17) cells. Further, we evaluated the clinical
implications of the alterations in this ratio.
Methodology/Principal Findings: Nine patients seropositive for hepatitis B e antigen received entecavir monotherapy for
12 months and the percentages of Tregs and Th17 cells as well as the HBV-specific IL-17 productions in these patients were
longitudinally analyzed. The entecavir-induced suppression of HBV replication was accompanied by a rapid increase in the
number of Th17 cells, together with a decrease in Treg cells, which lead to a significant reduction of Treg/Th17 ratios. In
addition, peripheral blood mononuclear cells (PBMCs) exhibited a decreased IL-17 production upon stimulation with the
HBV core antigen in vitro.
Conclusions: The inhibition of viral replication results in an increase in Th17 cells and concomitant decrease in Treg cells.
This imbalance of Treg cells to Th17 cells might have an important role in HBV persistence during entecavir treatment.
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Introduction
Patients who are chronically infected with hepatitis B virus
(HBV) are at a risk of developing liver cirrhosis and hepatocellular
carcinoma owing to many factors. One such factor is the host
immune response, which is induced by viral persistence; it is
related to the chronic inflammatory state of the patient and
influences both the clinical outcome of HBV infection and clinical
antiviral efficacy [1–3]. Antiviral treatment with nucleos(t)ide
analogs is one of the therapeutic options for patients with chronic
hepatitis B (CHB). These drugs effectively suppress HBV
replication, alleviate liver injury, and decelerate disease progres-
sion. However, CHB patients often exhibit varied responses to
these drugs [4,5]. Therefore, the identification of an early
immunologic marker associated with the clinical outcomes of the
antiviral therapy is critical for the development of improved
clinical management and therapeutic options.
Helper CD4
+ T cells can orchestrate host immune responses
through the release of distinct cytokine profiles. Recent studies
have described 2 additional subsets—regulatory T cells (Tregs)
and interleukin (IL)-17-producing CD4
+ T helper (Th17) cells
[6,7]—and have shown the reciprocal relationships between T
helper subsets and the outcome to anti-HBV therapy [8,9]. Recent
studies have shown that CHB patients have increased percentages
of Tregs in their peripheral blood and liver [10–13]. The increased
levels of Tregs, which is associated with increased HBV-DNA
levels, can inhibit the HBV-specific immune response in a dose-
dependent manner, and the depletion of Tregs results in increased
HBV-specific CD4
+ and CD8
+ T-cell proliferation and IFN-c
production. Adefovir-induced viral load reduction lead to the
decline in the number of circulating Tregs together with a partial
recovery of the immune response [13,14]. These findings,
therefore, suggested that Tregs actively participate in regulating
anti-HBV response. Furthermore, Th17 cells are significantly
increased in CHB patients and are considered to be important
factors triggering liver damage [15]. However, to date, the role of
Th17 cells during antiviral therapy remain unknown. Tregs and
Th17 cells are closely associated with each other, and tumor
growth factor (TGF)-b orchestrates the differentiation of both
these cells in a concentration-dependent manner [16–18]. Low
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promote IL-23R expression, thereby favoring Th17 cell differen-
tiation. However, increased concentrations of TGF-b repress IL-
23R expression and favor the generation of Tregs. Considering all
these evidences together, we hypothesize that an imbalance of
Th17 cells and Tregs may exist and may play a role in regulating
the immune response during anti-HBV therapy.
Entecavir is a carbocyclic analog of 29-deoxyguanosine, and it is
more potent than lamivudine and adefovir against HBV
replication. Currently, entecavir is used as the first-line anti-
HBV therapy [19–22]. In our study, we aimed to investigate the
influence of the decrease in the viral load on the percentages of
Tregs and Th17 cells, and thereby assess the effectiveness of
antiviral therapy in CHB patients.
Methods
Patients
Twenty-eight treatment-naive patients with CHB who visited
the Beijing 302 Hospital (Beijing, China) were enrolled in this
study. All patients were seropositive for hepatitis B surface antigen
(HBsAg) and hepatitis e surface antigen (HBeAg), in which nine
patients were followed serially with protocol visits for 12 months
continuously during the course of the antiviral treatment with a
nucleoside analogue (entecavir, 0.5 mg/day). They were 6 men
and 3 women (mean age, 33.365.2 years) without concurrent
HCV, hepatitis G virus, hepatitis D virus, HIV-1 infections and
autoimmune liver diseases. At baseline, their HBV-DNA levels
were .2610
4 IU/ml (range, 7.17610
5–8.34610
8 IU/ml) and
alanine aminotransferase (ALT) levels were twice (range, 83–
369 U/L) the upper limit of the normal levels. Twenty-six healthy
individuals were enrolled as normal control (HC). The study
protocol was approved by Beijing 302 Hospital Research Ethnics
Committee, written informed consents for therapy and study was
obtained from each patient. The clinical characteristics of these
subjects are listed in Table 1.
Flow cytometric analysis
All antibodies were purchased from BD Biosciences (San Jose,
CA), except for phycoerythrin (PE)-conjugated anti-IL-17A and
fluorescein isothiocyanate (FITC)-conjugated anti-FoxP3 from
eBioscience (San Diego, CA). For immunostaining of intracellular
IL-17A, fresh heparinized peripheral blood (200 ml) was incubated
with phorbol-12-myristate-13-acetate (PMA, 300 ng/ml, Sigma-
Aldrich, St. Louis, MO) and ionomycin (1 mg/ml, Sigma-Aldrich)
in 800 ml of RPMI 1640 medium supplemented with 10% fetal
calf serum for 6 hours. Monensin (0.4 mM, BD PharMingen, San
Diego, CA) was added during the first hour of incubation. The
blood cells were then lysed with FACS
TM lysing solution (BD
PharMingen), further permeabilized and stained with the
corresponding intracellular antibody. For intracellular FoxP3
staining, peripheral blood (200 mL) was firstly lysed with FACS
TM
lysing solution (BD PharMingen), and then treated with
eBioscience fix/perm (eBiosciences) according to the manufactur-
er’s instructions. Cells were incubated with FITC-conjugated anti-
FoxP3 for 30 min, fixed, and analyzed using FACSCalibur (BD
Biosciences) and FlowJo software (Tristar, USA) by following the
protocol described in a previous study [15].
Cell stimulation
Freshly isolated peripheral blood mononuclear cells (PBMCs)
were stimulated with HBcAg as described in a previous study [15].
Briefly, PBMCs were cultured in triplicate in 96-well plates at a
concentration of 5610
5 cells/well in 200 ml of RPMI 1640
containing 10% fetal calf serum. The cells were stimulated with
HBcAg (5 mg/ml, ARP, Belmont, MA) and cultured for 3 days.
After 3 days of incubation, the supernatants were collected for the
measurement of serum IL-17 levels.
Enzyme-linked immunosorbent assay
The levels of IL-17 in the plasma and supernatants were
measured using quantitative sandwich enzyme-linked immuno-
sorbent assay (ELISA) by following the manufacturer’s instructions
(R&D Systems, Minneapolis, MN). The minimal detectable
concentration of IL-17 was 15 pg/ml. The intra-assay and inter-
assay coefficients of variation for all the ELISAs were ,5% and
,10%, respectively. All samples were measured in duplicate.
Virological and immunological assessment
The levels of HBsAg, anti-HBs, anti-HBc, HBeAg, anti-HBe,
anti-HCV, anti-HDV, anti-HGV, and anti-HIV were measured
using commercially available kits (Abbot Laboratories, North
Chicago, IL). HBV-DNA levels were determined using real-time
polymerase chain reaction (Amplicor, Roche) according to the
manufacturer’s instructions. The threshold of the HBV DNA
detection limit was 100 IU/ml [23].
Statistical Analysis
All data were analyzed using SPSS software (SPSS Inc.,
Chicago, IL). For comparison between different time points,
statistical comparison was analyzed using the Wilcoxon matched
pairs test. The correlations between the variables were evaluated
using the Spearman rank correlation test. For all tests, two-sided P
values less than 0.05 were considered significant.
Results
Treg/Th17 ratios were decreased in CHB patients
compared with HCs
We measured the frequency of IL-17A-producing cells (Th17)
and FoxP3-positive cells (Tregs) within the CD4 subset using flow
cytometry. All subjects clearly displayed the two CD4 T-cell
subsets (Figure 1A). We showed a significantly higher frequency of
Th17 cells in CHB patients (5.16%62.21) when compared with
healthy subjects (2.04%60.56, p,0.001) (Figure 1B). Despite
Tregs can generate from the same naı ¨ve T cell poll that generates
Th17 cells, we found no significant differences in Treg frequencies
when comparing CHB patients with HCs (Figure 1C). To tie Treg
cells with Th17 cells, we use the ratio of Treg cells to Th17 cells as
Table 1. Clinical characteristics of the populations enrolled in
the study.
Group HC CHB
Case 26 28
Sex (male/female) 16/10 18/10
Age (years) 31 (20–44) 30 (18–46)
ALT (U/L) 21 (10–37) 119 (81–443) *
HBV DNA (IU/ml) ND 3.206107
(2.576105–2.016109) *
Data are shown as median and range. HC: healthy control; CHB: chronic
hepatitis B; ND: not determined.
*P,0.05 vs. CHB subjects.
doi:10.1371/journal.pone.0013869.t001
Ratio of Treg to Th17 Cells
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(Figure 1D).
HBV-DNA levels decreased and alanine aminotransferase
levels normalized during entecavir treatment
For entecavir-treated patients, the levels of serum HBV DNA
and alanine aminotransferase level (ALT) were determined at the
baseline, as well as at 1, 3, 6, 9, and 12 months after entecavir
treatment. In all patients, the HBV replication at month 1 was
considerably lower than that at baseline; the median reduction of
HBV DNA level was 3.2 log10 IU/mL, which gradually reduced
to 2.3 log10 IU/mL at 3 months, and this decrease was paralleled
by a decrease in the serum ALT levels. At 6 months of treatment,
HBV DNA was undetectable in 8 patients (89%) and ALT levels
were normalized in 7 (78%) patients. At the end of the follow-up,
loss of serum HBeAg was achieved in 7 patients, and seroconver-
sion from HBeAg to anti-HBeAg was achieved in 2 patients. Loss
of serum HBsAg during the treatment was not achieved in any
patient. The changes in the levels of clinical markers in these
subjects are listed in Figure 2.
Serial fluctuations of peripheral blood T helper subsets
during entecavir-induced viral load reduction
To assess the effect of entecavir treatment on T-helper subsets,
we longitudinally determined the proportion of Th17 cells and
Tregs in the blood samples of these patients by using the flow
cytometric assay. All patients showed distinct compositions of
CD4
+ T-cell subsets at different treatment time points. Interest-
ingly, the frequencies of Th17 cells reached the maximal peak at
month 1 and the frequencies at all time points from month 1 to
month 9 remained higher than those at the baseline and at the
endpoint (Figure 3A). In contrast, the frequencies of Tregs
gradually decreased from the baseline to month 6 and subse-
quently, they showed a reverse ‘‘V’’-type change with the maximal
peak at month 9 (Figure 3B).
Tregs and Th17 cells may be generated from the same
precursor T cells. Therefore, we investigated the reciprocal
relationship between Tregs and Th17 cells during the treatment.
Figure 1. The Treg/Th17 ratio was decreased in CHB patients. (A) Representative dot plots of IL-17A and FoxP3 expression in peripheral CD4
+
T cells of HC subjects and CHB patients. The values in the quadrants indicate the percentage of each CD4
+ T-cell subset. (B) Pooled data indicate the
percentages of Th17 cells in HC and CHB patients. (C) Pooled data indicate the percentages of Treg cells in HC and CHB patients. (D) The ratio of
circulating Treg cells to Th17 cells is significantly lower in CHB patients. Horizontal bars represent the median values of indicated index.
doi:10.1371/journal.pone.0013869.g001
Figure 2. Clinical characteristics of chronic HBV patients
undergoing entecavir therapy: (A) the serum HBV-DNA levels
of the 9 patients at the baseline and during the 12 months of
entecavir therapy; and (B) the serum ALT levels of the 9
patients at the baseline and during the 12 months of entecavir
therapy. The levels of HBV DNA and ALT at month 1 were significantly
lower than those at the baseline (P,0.05). Each symbol represents an
individual and each line represents changes in an individual patient’s
DNA or ALT levels from the baseline to the endpoint (month 12). ALT,
alanine aminotransferase; HBV, hepatitis B virus.
doi:10.1371/journal.pone.0013869.g002
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month 3 and exhibited a reverse ‘‘V’’-type change. We further
dissected the association between the Treg/Th17 ratios and
clinical implications in these CHB patients and found that the
Treg/Th17 ratios were positively correlated with HBV-DNA
levels during the period from the baseline to month 3.
IL-17 production decreased during entecavir-induced
viral load reduction
To determine the levels of HBV-specific IL-17, PBMCs
collected at the baseline and during therapy were stimulated
with HBcAg. The HBcAg-specific IL-17 production at month 1
was higher than that at the baseline, which was consistent with
the total frequencies of IL-17-producing cells, as determined by
intracellular staining. However, the HBcAg-specific IL-17
production gradually decreased from month 3 to the end of
the follow-up period. Therefore, the HBcAg-specific IL-17
productions showed a reverse ‘‘V’’-type change with the
maximal peak at month 1 (Figure 5A); the serum IL-17 levels,
as determined by ELISA, also showed a similar trend during
entecavir treatment (Figure 5B).
Discussion
The advantage of our study design is that by longitudinally
monitoring the impact of treatment-induced suppression of HBV
replication with direct antivirals (entecavir), we were able to define
the cause-effect relationship between the viral load and Treg/
Th17 ratio. Our findings showed that the Treg/Th17 ratio was
decreased in CHB patients. In addition, entecavir-induced
suppression of viral replication resulted in an increase in Th17
cells and concomitant decrease in Treg cells, which was manifested
by a profound decrease of the Treg/Th17 ratios. Thus, this
imbalance of Treg cells to Th17 cells might play an important role
in HBV persistence during entecavir treatment.
Increasing evidences have shown that the host immunity
influences antiviral efficacy in CHB patients. We believed that
restoration of HBV-specific T-cell response during antiviral
therapy is associated with CD4
+ T-cell activity. For example,
lamivudine was found to increase the CD4
+ T-cell response at the
initial 1–2 weeks of antiviral therapy [24]. Furthermore, the
combination therapy of adefovir dipivoxil and emtricitabine led to
an increase in the CD4
+ T-cell activity [25]. Previous study has
shown that adefovir treatment can partially reduce the frequency
of the circulating Tregs and that this reduction occurs concom-
itantly with an increase in the HBV-specific T cell response
[13,14]. In our study, we also found that entecavir treatment could
partially reduce the frequency of circulating Tregs within 6
months. Th17 cells have been associated with the immunopath-
ological changes in several chronic inflammatory diseases and
could conceivably play a major role in the inflammatory state
associated with liver disease [15,26–29]. Therefore, we hypothe-
sized that the number of Th17 cells may decrease during anti-
HBV therapy. Unexpectedly, we found that the total number of
Th17 cells was indeed increased from month 1 and the total
number of these cells throughout the period from month 1 to
month 9 was higher than that at the baseline; subsequently, their
levels declined to the baseline levels at approximately 12 months of
therapy. Given the mechanism of action of entecavir, which
Figure 3. The frequencies of Th17 cells and Tregs in entecavir-
treated patients during the course of therapy: (A) The
frequencies of Th17 cells were observed from the baseline to
the endpoint (month 12). The total number of Th17 cells was rapidly
increased at month 1 and were higher than the baseline from month 1
to month 9; subsequently, their levels declined to the baseline levels at
approximately the 12
th month of therapy. The P values between
different time points are shown. (B) The frequencies of Th17 cells were
observed from the baseline to the endpoint (month 12). The P values
between different time points are shown. (A and B) Each symbol
represents one individual and each line represents the changes in an
individual patient’s Th17 frequencies or Treg frequencies from the
baseline to the endpoint (month 12). The solid line depicts the mean
percentages of Th17 cells and Tregs during the antiviral therapy.
doi:10.1371/journal.pone.0013869.g003
Figure 4. Correlations between Treg/Th17 ratios and HBV-DNA
levels. The average Treg/Th17 ratios and HBV-DNA levels for each time
point are represented by the diamond symbols. The reduction in the
Treg/Th17 ratios from the baseline to month 3 correlates with the
reduction in the HBV-DNA levels. Error bars illustrate the standard
errors. * P=0.039 for month 1, P=0.016 for month 3, P=0.006 for
month 6 compared with the baseline. 1 P=0.038 for month 3, P=0.015
for month 6 compared with the baseline.
doi:10.1371/journal.pone.0013869.g004
Ratio of Treg to Th17 Cells
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in a siginificant fall in the HBV-DNA levels and that this in turn
leads to a change in the cytokine environment, which, on one
hand, favor the increase in the numbers of Th17 cells, on the other
hand, may lead to a decrease in Tregs. This is similar to what has
been reported in autoimmune disease [30]. Interestingly, there was
a temporary increased HBV-specific IL-17 production at month 1,
which occurs concomitantly with the decrease in the numbers of
Tregs. However, the temporary increased HBV-specific IL-17
production gradually declined from month 1 to the baseline level.
Together with our recent study in which we observed that the
response of Th17 cells was influenced by the inflammatory
environment (unpublished data), future studies should be under-
taken to elucidate the factors that suppress the activity of Th17
cells during anti-HBV therapy.
Recent reports have shown that Treg/Th17 ratio may be a
useful marker for assessing the severity of diseases in animal
models and human diseases, and important mechanisms were
postulated to explain the skewed Treg/Th17 ratios [31,32].
However, no study has described the significance of the skewed
Treg/Th17 ratios during antiviral therapy in CHB patients. In this
study, we highlighted the existing direct relationship between
Treg/Th17 ratios and HBV-DNA levels. We observed that Treg/
Th17 ratios tended to decrease during the first 3 months of
treatment in all patients. Interestingly, the Treg/Th17 ratios seem
to increase after HBeAg loss. HBeAg was considered to be a
tolerogen in HBV infection. However, the limited sample
population of entecavir-treated patients in our study precluded
us from testing the relationship between HBeAg and Treg/Th17
ratios. We will further investigate the Treg/Th17 ratios before and
after seroconversion in the absence of changes in the HBV-DNA
levels.
In conclusion, this study highlights that the viral load affects the
Treg/Th17 ratios during antiviral treatment in CHB patients.
Our findings reveal a strong correlation between HBV load and
the Treg/Th17 ratios during antiviral treatment and these data
indicated the imbalance of Treg cells to Th17 cells might play an
important role in HBV persistence.
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